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While the microtubule-binding capacity of the protein tau has been known for many years, new functions of
tau in signaling and cytoskeletal organization have recently emerged. In this review, we highlight these
functions and the potential roles of tau in neurodegenerative disease.We also discuss the therapeutic poten-
tial of drugs targeting various aspects of tau biology.A Microtubule-Associated Protein Involved in Disease
The microtubule-associated protein tau was identified as
a microtubule-assembly factor in the mid-1970s (Weingarten
et al., 1975; Witman et al., 1976). Subsequently, hyperphos-
phorylated, insoluble, filamentous tau was shown to be the
main component of neurofibrillary tangles (NFTs), a pathological
hallmark of Alzheimer’s disease (AD) (Grundke-Iqbal et al., 1986;
Kondo et al., 1988; Lee et al., 1991; Nukina and Ihara, 1986;
Wood et al., 1986). Neurodegenerative disorders with tau inclu-
sions are referred to as tauopathies (Lee et al., 2001). These
include AD; frontotemporal lobar degeneration with tau inclu-
sions (FTLD-tau) such as Pick’s disease, progressive supranu-
clear palsy, and corticobasal degeneration; agyrophillic grain
disease; some prion diseases; amyotrophic lateral sclerosis/
parkinsonism-dementia complex; chronic traumatic encepha-
lopathy; and some genetic forms of Parkinson’s disease (Lee
et al., 2001; Omalu et al., 2011; Rajput et al., 2006; Santpere
and Ferrer, 2009). Although associations per se cannot prove
cause-effect relationships, tau inclusions are widely thought to
contribute to the pathogenesis of these disorders because
they occur in specific brain regions whose functions are altered
by these conditions, and NFT formation correlates with the dura-
tion and progression of AD (Giannakopoulos et al., 2003; Ihara,
2001). Tau inclusions also appear to modulate the clinical
features of other neurodegenerative diseases. In dementia with
Lewy bodies, an a-synuclein disorder, accumulation of insoluble
tau inclusions is associated with a more AD-like phenotype
(Merdes et al., 2003).
Tau is expressed in the central and peripheral nervous system
and, to a lesser extent, in kidney, lung, and testis (Gu et al., 1996).
It is most abundant in neuronal axons (Lee et al., 2001; Trojanow-
ski et al., 1989) but can also be found in neuronal somatoden-
dritic compartments (Tashiro et al., 1997) and in oligodendro-
cytes (Klein et al., 2002). Tau can be subdivided into four
regions: an N-terminal projection region, a proline-rich domain,
a microtubule-binding domain (MBD), and a C-terminal region
(Mandelkow et al., 1996). Alternative splicing around the
N-terminal region and MBD generates six main isoforms in adult
human brain (Goedert et al., 1989). Tau isoforms are named
by how many microtubule binding repeat sequences are ex-
pressed (termed R) and by which N-terminal exons are included410 Neuron 70, May 12, 2011 ª2011 Elsevier Inc.(termed N) (Figure 1). For example, 3R tau has three microtubule
binding repeat sequences, while 4R tau has four due to inclusion
of exon 10. 0N tau includes no N-terminal exons, 1N tau exon 2,
and 2N tau exons 2 and 3 (Lee et al., 2001). Tau mutations are
numbered by their location in 4R2N human tau (Lee et al.,
2001). Six additional isoforms are formed by alternative splicing
around exon 6, resulting in a total of 12 tau isoforms expressed in
brain (Wei and Andreadis, 1998), although these additional splice
variants have not yet been widely studied.
Physiological tau has an intrinsically disordered structure and
is subject to a complex array of posttranslational modifications.
Many serine and threonine residues on tau are phosphorylated
by a variety of kinases in both physiological and pathological
conditions (for a comprehensive table of tau phosphoryla-
tion and corresponding kinases, see http://cnr.iop.kcl.ac.uk/
hangerlab/tautable). Tau is also posttranslationally modified by
tyrosine phosphorylation (Lee et al., 2004), acetylation (Cohen
et al., 2011; Min et al., 2010), cross-linking by transglutaminase
(Wilhelmus et al., 2009), glycation (Ledesma et al., 1994), isom-
erization (Miyasaka et al., 2005b), nitration (Reyes et al., 2008),
sumoylation (Dorval and Fraser, 2006), O-GlcNAcylation (Arnold
et al., 1996), and ubiquitination (Cripps et al., 2006). The diversity
of these modifications suggests that tau is highly regulated.
Tau can bind to the outside and, possibly, also the inside of
microtubules, with its N- and C-terminal regions projecting
outward (Kar et al., 2003; Santarella et al., 2004). Its N-terminal
region can associate with the cell membrane, likely as part of
a membrane-associated complex (Figure 1), and regulate the
spacing between microtubules (Al-Bassam et al., 2002; Frappier
et al., 1994; Maas et al., 2000). Its proline-rich domain includes
many phosphorylation sites (Augustinack et al., 2002; Biernat
et al., 1992) and can bind to SH3 domains of other proteins
(Reynolds et al., 2008), including the tyrosine kinase Fyn (Lee
et al., 1998). Tau’s ability to bind microtubules depends on the
MBD and on adjacent regions (Gustke et al., 1994). The tandem
repeat sequences within the MBD are thought to directly bind
microtubules through their positive net charge, which interacts
with negatively charged residues in tubulin (Jho et al., 2010;
Kar et al., 2003). Phosphorylation of tau regulates its binding to
microtubules and is also associated with tau aggregation in
disease. Phosphorylation of tau in and around the MBD may
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Figure 1. Tau Structure and Function
Tau is an intrinsically disordered protein that can be
alternatively spliced at N terminal exons (N1, 2) and the
microtubule repeat domains (R). The domains of tau bind
many different types of molecules, suggesting a central
role in signaling pathways and cytoskeletal organization.
The diversity of tau binding partners is highlighted in
Table 1. N-term, N terminus; C-term, C terminus; SH3,
protein SH3 domain.
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conformation of the MBD of tau (Fischer et al., 2009), detaching
tau from microtubules. The detached tau accumulates in
neuronal cell bodies and neurites, forming insoluble filaments
and, ultimately, NFTs (Lee et al., 2001; von Bergen et al.,
2005). The MBD also contains PHF6 (VQIVYK) and PHF6*
(VQIINK), critical sequences that can assume the beta-sheet
structures necessary for tau aggregation and formation of path-
ological inclusions (von Bergen et al., 2001, 2005).
Evidence for Multiple Functions of Tau
Although tau has been studied ever more intensely in recent
years, its precise functions and roles have, if anything, become
more mysterious. Some of its activities are known in great
molecular detail but were established in rather reductionist para-
digms, and their in vivo significance remains uncertain. Other
functions were revealed by analysis of tau knockout mice, but
the precise mechanisms are poorly understood. A major advan-
tage of tau knockout models is that they can reveal unique func-
tions of tau that are not redundant with the functions of other
proteins. For example, tau reduction prevents behavioral deficits
in several models of AD (see below), suggesting that unique
functions of tau are important in the pathogenesis of this condi-
tion. It remains controversial whether animal models with high
levels of tau overexpression can provide relevant insights into
human conditions in which such overexpression does not
occur. However, the accumulation and abnormal distribution of
hyperphosphorylated and aggregated tau in these models
does simulate key aspects of human tauopathies. Concerns
may also be raised about the relevance of studies investigating
tau in nonneuronal cells. Although neurons are probably the
most relevant cell type to study in relation to tauopathies,
some tauopathies are associated with tau pathology in glial cells
(Higuchi et al., 2005), and the proteins that interact with tau in
different cell types likely overlap.
Tau has numerous binding partners (Table 1), including
signaling molecules, cytoskeletal elements and lipids, suggest-
ing that it is a multifunctional protein. Indeed, tau can bind toNand affect cytoskeletal components and regu-
late signaling pathways by acting as a protein
scaffold for signaling complexes; tau binding
also activates or inhibits several enzymes.
Cytoskeletal Binding Functions
The most extensively described activity of tau—
binding to microtubules—occurs in vitro and
in vivo. In fact, the majority of tau in the cell is
bound to microtubules. In cell-free conditions,
this microtubule binding activity promotesmicrotubule assembly and stability (Weingarten et al., 1975).
However, in cell culture, tau colocalizes with those microtubules
that are most dynamic and most susceptible to drug-induced
depolymerization (Kempf et al., 1996). Moreover, the population
of tau-bound microtubules has the highest basal turnover rate of
any microtubule population, both in rat primary neuronal culture
and in mouse hippocampus in vivo (Fanara et al., 2010), raising
doubts about the essential role of tau in microtubule stabilization
postulated on the basis of in vitro findings. In addition, knock-
down of tau by siRNA is not lethal to primary neurons in culture
and does not decrease the number of microtubules or their
polymerization state (King et al., 2006; Qiang et al., 2006).
Thus, microtubule stabilization may not be a critical function of
tau in vivo.
The in vivo functions of tau appear to overlap with those of
MAP1B, another microtubule-associated protein found in axons.
Complete ablation of tau by homologous recombination does
not significantly impair longevity or most critical brain functions,
but clearly worsens the MAP1B knockout phenotype of prema-
ture mortality and brain dysgenesis (Takei et al., 2000). Knockout
of both tau and MAP1B results in severe brain dysgenesis and is
lethal within the first month of life. Assuming that this phenotype
relates to the microtubule-binding activities of tau and MAP1B,
which is uncertain, it is reasonable to speculate that MAP1B is
more important for microtubule stabilization than tau and that
their overlapping functions are critical for postnatal brainmatura-
tion. However, because of the early lethality, it is impossible to
draw firm conclusions from the double-knockout phenotype on
the functions of tau and MAP1B in the adult or aging brain.
In principle, tau’s binding to microtubules could regulate
axonal transport. Tau can interfere with the binding of motor
proteins to microtubules (Dixit et al., 2008; Ebneth et al., 1998),
and there is a gradient of tau along the axon; the highest levels
are closest to the synapse (Mandell and Banker, 1996). This
distribution might facilitate the detachment of motor proteins
from their cargo near the presynaptic terminal, increasing axonal
transport efficiency (Dixit et al., 2008). However, ablation of tau
does not alter axonal transport in primary neuronal cultureeuron 70, May 12, 2011 ª2011 Elsevier Inc. 411
Table 1. Partial List of Tau Binding Partners
Tau Binding
Partners
Function of
Binding Partner References
ApoE3 Lipid carrier Fleming et al., 1996;
Strittmatter et al., 1994
Beta tubulin Cytoskeleton Kar et al., 2003
cSrc Src-family kinase Lee et al., 1998;
Reynolds et al., 2008
F-actin Cytoskeleton Fulga et al., 2007
Fgr Src-family kinase Reynolds et al., 2008
Fyn Src-family kinase Lee et al., 1998;
Reynolds et al., 2008
Growth factor
receptor-bound
protein 2 (Grb2)
Adaptor protein
for growth factor
signaling
Reynolds et al., 2008
Lck Src-family kinase Lee et al., 1998
p85a Regulatory subunit
of PI3K
Reynolds et al., 2008
Phosphatidylinositol Signaling lipid Surridge and Burns, 1994
Phosphatidylinositol
bisphosphate
Signaling lipid Flanagan et al., 1997
PLCg Cleaves
phospholipids
into signaling
molecules
Hwang et al., 1996;
Jenkins and Johnson,
1998; Reynolds
et al., 2008
Figure 2. Endogenous Tau Exists in Dendritic Spines
Tau immunoprecipitates with PSD95, a postsynaptic protein, and regulates
the association of PSD-95 with NMDAR subunits and the tyrosine kinase Fyn.
Overexpression of a human N-terminal truncation of tau (Dtau74, light gray) or
knocking out tau (tau–/–, dark gray) reduced the amount of NR1, NR2a, NR2b,
and Fyn within PSD95 complexes as compared with wild-type mice (white;
*p < 0.005, Student’s t test). Error bars represent standard error of the mean.
From Ittner et al. (2010) with permission from Elsevier.
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essential role of tau in this physiological function less likely.
Tau can also bind to and bundle actin filaments (Fulga et al.,
2007; He et al., 2009; Kotani et al., 1985), activities mediated
primarily by its MBD (Farias et al., 2002; Yu and Rasenick,
2006) and assisted by the adjacent proline-rich domain (He
et al., 2009; Figure 1). It is possible that tau connectsmicrotubule
and actin filament networks (Farias et al., 2002).
Modulation of Signaling Pathways through Scaffolding
Tau could also act as a protein scaffold, and regulation of its
binding partners may alter signaling pathways. For example,
tau modulates the activity of Src family kinases. In mouse
brain tissues, tau coimmunoprecipitates with both the tyrosine
kinase Fyn and the scaffolding protein PSD-95, and in the
absence of tau, Fyn can no longer traffic into postsynaptic sites
in dendrites (Figure 2; Ittner et al., 2010). The authors speculated
that tau normally tethers Fyn to PSD-95/NMDA receptor
signaling complexes. Although very little tau is normally present
in dendrites, it may be enough to ensure proper localization of
postsynaptic components (Ittner et al., 2010). Similarly, tau
acts as a protein scaffold in oligodendrocytes, connecting Fyn
and microtubules to enable process extension (Klein et al.,
2002). In cell culture, tau binds to and activates both cSrc and
Fyn and facilitates cSrc-mediated actin rearrangements follow-
ing platelet-derived growth factor stimulation (Sharma et al.,
2007).
Tau may also regulate signaling cascades that control neurite
extension, although this is a somewhat controversial area. Some
investigators have reported a defect in neurite extension in tau
knockout neurons in vitro (Dawson et al., 2001), whereas others412 Neuron 70, May 12, 2011 ª2011 Elsevier Inc.found no such defect despite observing decreased numbers of
microtubules (Harada et al., 1994). Knockdown of tau by siRNA
decreased the length of axons (Qiang et al., 2006) but not the
number of microtubules (King et al., 2006; Qiang et al., 2006),
and overexpression of tau promoted neurite extension in cell
culture (Brandt et al., 1995). These effects may relate to tau’s
ability to thwart microtubule-severing proteins (Qiang et al.,
2006) but could also involve facilitation of nerve growth factor
(NGF) signaling.
In PC12 cells, overexpression of full-length tauwas associated
with normal neurite extension and an increased number of
neurites per cell, whereas overexpression of the N terminus of
tau suppressed NGF-induced neurite extension (Brandt et al.,
1995). Thus, increased levels of tau may enhance NGF function,
whereas the N terminus of tau may impair NGF signaling,
possibly by a dominant-negative mechanism. Enhancement of
NGF signaling by tau may involve increased association of tau
with actin filaments, which occurs after stimulation with NGF
and is mainly mediated by the MBD (Yu and Rasenick, 2006)
rather than the N terminus. In PC12 cells, tau facilitates signaling
through receptors for NGF and epidermal growth factor (EGF),
thereby increasing activity in the mitogen-activated protein
kinase (MAPK) pathway (Leugers and Lee, 2010). Stimulation
of PC12 cells with NGF or EGF causes tau phosphorylation at
T231, a modification necessary for the growth factor-induced
activation of the Ras-MAPK pathway (Leugers and Lee, 2010),
nicely illustrating the functional significance of a single tau phos-
phorylation site. As tau is not known to directly interact with
growth factor receptors, it may facilitate signaling by binding
to adaptor proteins such as Grb2 (Reynolds et al., 2008). The
enhancement of growth factor signaling by increased tau
expression may explain why several forms of chemotherapy-
naive cancer cells overexpress tau (Rouzier et al., 2005; Souter
and Lee, 2009).
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Tau binds phospholipase C (PLC) g in human neuroblastoma
(SH-SY5Y) cells (Jenkins and Johnson, 1998). Under cell-free
conditions and in the presence of unsaturated fatty acids, tau
activates PLCg independently of the tyrosine phosphorylation
usually required to activate this enzyme (Hwang et al., 1996).
At high tau concentrations, this activation does not require fatty
acids (Hwang et al., 1996) and may involve binding of tau to both
the enzyme and the substrates phosphatidylinositol (Surridge
and Burns, 1994) or phosphatidylinositol 4,5-bisphosphate
(Flanagan et al., 1997), which could facilitate the phospholipid
cleavage reaction. Activation of PLCg by tau was particularly
facilitated by arachidonic acid (Hwang et al., 1996). Arachidonic
acid is released from phospholipids by cytosolic phospholipase
A2, whose activity in the brain is increased in AD patients and
related mouse models (Sanchez-Mejia et al., 2008). Thus,
increased levels of tau and arachidonic acid may jointly increase
signaling through the PLCg pathway in AD.
Tau can also act as a direct enzyme inhibitor. For example,
it can bind to and inhibit histone deacetylase-6 (Perez et al.,
2009), which deacetylates tubulin and may regulate microtubule
stability (Perez et al., 2009). Thus, tau may affect microtubule
stability by a mechanism independent of tubulin binding,
although reports regarding the levels of acetylated tubulin in
tau knockout mice vary (Perez et al., 2009; Rapoport et al.,
2002).
Tau also appears to participate in the cellular response to heat
shock. During heat shock of neurons, tau bound DNA and facil-
itated DNA repair, and tau knockout neurons showed increased
DNA damage (Sultan et al., 2011). However, when cultured
neurons were allowed to recover from heat shock, tau knockout
actually protected against heat shock-induced cell damage, as
determined by measurements of neurite length and lactate
dehydrogenase release (Miao et al., 2010). Compared with
wild-type neurons, tau knockout neurons showed a delayed
and prolonged activation of Akt and less GSK3b activity during
recovery from heat shock (Miao et al., 2010), suggesting that
the protective effect of tau knockout may be upstream of Akt/
GSK3b phosphorylation. In sensory neurons of C. elegans, over-
expression of 4R0N tau decreased the response to touch, and
this phenotype was exacerbated by heat shock when tested
after a recovery period of 24 hr (Miyasaka et al., 2005a). These
results suggest that tau has a role in the cellular response to
heat shock, both during the insult and in the subsequent
recovery phase.
Adult Neurogenesis
Tau affects adult neurogenesis. Three-repeat tau is expressed
and highly phosphorylated in adult-born granule cells in the
dentate gyrus (Bullmann et al., 2007; Hong et al., 2010). In one
strain of tau knockout mice, adult neurogenesis was found to
be severely reduced (Hong et al., 2010). However, tau does not
appear to be needed for embryonic neurogenesis, as tau
knockout mice have grossly normal brain anatomy. The func-
tional significance of adult neurogenesis is a topic of intense
study and debate (Zhao et al., 2008). Notably, adult tau knockout
mice showed no deficits in a variety of learning and memory
paradigms (Dawson et al., 2010; Ittner et al., 2010; Roberson
et al., 2007, 2011).Mechanisms by Which Tau Contributes to Disease
As mentioned above, tau probably fulfills multiple functions and
may contribute to neuropathogenesis in multiple ways. In prin-
ciple, this might include both gain- and loss-of-function effects,
although the latter mechanism has recently been called into
question by several lines of experimental evidence. Furthermore,
tau does not act alone. For example, in AD it appears to enable
the pathogenic effects of both Ab and apolipoprotein E4 (apoE4)
(Andrews-Zwilling et al., 2010; Ittner et al., 2010; Roberson et al.,
2007, 2011).
Loss of Function
Aprominent theory about tau pathologywas that disease pheno-
typeswere caused by loss of tau function due to hyperphosphor-
ylation and sequestration of soluble tau (Zhang et al., 2005).
In many tauopathies, tau is hyperphosphorylated, which
releases tau from microtubules, apoE (Strittmatter et al., 1994),
Src (Bhaskar et al., 2005), and possibly other binding partners.
Although it is conceivable that this process results in loss of
specific tau functions, increased phosphorylation of tau per se
is probably not detrimental, as it occurs naturally during hiberna-
tion (Arendt et al., 2003) and fetal development (Yu et al., 2009).
Phosphorylated tau from AD brains may seed the aggregation of
control human tau (Alonso et al., 1996), but we are unaware of
any evidence that tau aggregation actually lowers levels of
soluble tau in vivo.
Recent experimental studies have shown more directly that
loss of tau function is an unlikely cause of neurodegeneration
and neuronal dysfunction. Longevity and behavioral functions
are among the most compelling outcome measures for the
evaluation of biologically meaningful processes affecting the
central nervous system. Complete ablation of tau in knockout
mice does not cause premature mortality or major neurological
deficits (Dawson et al., 2001; Harada et al., 1994; Ikegami
et al., 2000; Roberson et al., 2007, 2011; Yuan et al., 2008).
Four independent tau knockout lines have been established
and most of them have normal behavior throughout most of their
lives (Table 2). Only one of these lines was reported to have
motor deficits, hyperactivity in the open field test, and learning
impairments in contextual fear conditioning at 10–11 weeks of
age (Ikegami et al., 2000). Using fear conditioning to assess
learning and memory in hyperactive mice is problematic
because the hyperactivity confounds the interpretation of dimin-
ished freezing (Rudy et al., 2004). Because tau ablation has so
little impact on neural functions, two of the tau knockout lines
were actually generated as tools for neuron-specific expression
of EGFP (Tucker et al., 2001) or Cre (Muramatsu et al., 2008).
Although axonal abnormalities have been reported in the
cingulate cortex and genu of the corpus callosum of 10- and
12-month-old tau knockout mice, these mice showed no behav-
ioral deficits in the rotarod test, Morris water maze, or radial arm
water maze (Dawson et al., 2010). To our knowledge, no deficits
of any kind have been identified in hemizygous knockout mice,
which have roughly half normal tau levels (Ikegami et al., 2000;
Roberson et al., 2007).
Based on electrophysiological recordings in acute hippo-
campal slices, tau knockout mice and wild-type controls have
similar NMDA/AMPA receptor currents, synaptic transmission
strength, and short-term as well as long-term synaptic plasticityNeuron 70, May 12, 2011 ª2011 Elsevier Inc. 413
Table 2. Behavioral Tests in Tau Knockout Mice
Mouse Line Age Behavioral Test Result
Tau knockout line 1
(Harada et al., 1994)
10–11 weeks Balance beam Impaired motor function (Ikegami et al., 2000)
10–11 weeks Contextual fear conditioning Impaired learning/memory (Ikegami et al., 2000)
10–11 weeks Open field Hyperactive (Ikegami et al., 2000)
10–11 weeks Wire hang Impaired motor function (Ikegami et al., 2000)
Tau knockout line 2
(Dawson et al., 2001)
4–7 months,
12–16 months
Elevated plus maze Normal anxiety and exploration (Roberson et al., 2007)
4–7 months,
10–12 months
Morris water maze Normal learning/memory (Roberson et al., 2007)
Normal learning/memory (Dawson et al., 2010)
10–12 months Rotarod Normal motor function (Dawson et al., 2010)
10–12 months Radial arm water maze Normal learning/memory (Dawson et al., 2010)
4–7 months Y maze Normal activity (Roberson et al., 2007)
Tau knockout/EGFP knockin line
(Tucker et al., 2001)
4.5–7.5 months Elevated plus maze Normal anxiety and exploration (Roberson et al., 2011)
4.5–7.5 months Novel object recognition Normal learning/memory (Roberson et al., 2011)
8 months T maze Normal learning/memory (Ittner et al., 2010)
Tau knockout/Cre knockin line
(Muramatsu et al., 2008)
— None —
Table 3. Electrophysiological Abnormalities of hAPP-J20 Mice
Prevented by Tau Knockout (Roberson et al., 2011)a
Electrophysiological
Measureb
Tau–/–
Mice
hAPP/Tau+/+
Mice
hAPP/Tau–/–
Mice
Action potential-driven
IPSC frequency
Normal Y Normal
Coastline burst index Y [ Y
EEG epileptiform
activity (cortex)
Normal [ Normal
eEPSC amplitude Normal [ Normal
eIPSC amplitude Normal Y Normal
Long-term potentiation Normal Y Normal
mEPSC frequency Normal Y Normal
mIPSC frequency Normal [ Normal
NMDAR/AMPAR ratio Normal Y Normal
Paired-pulse ratio Normal Y Normal
sIPSC frequency [ Y [
Synaptic strength (CA1) Normal Y Normal
Similar results were observed after exposure of hippocampal slices to
recombinant Ab aggregates (Shipton et al., 2011). EPSC, excitatory post-
synaptic current; IPSC, inhibitory postsynaptic current; e, evoked; m,
miniature; s, spontaneous.
aRelative to Tau+/+ mice.
bRecorded at perforant path to granule cell synapse in dentate gyrus
unless indicated otherwise. All recordings were obtained in acute hippo-
campal slices.
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ingly, tau knockout mice are more resistant to seizures caused
by disinhibition, excitotoxins, or amyloid-b (Ab) peptides than
wild-type mice (Figure 3A; Ittner et al., 2010; Roberson et al.,
2007, 2011). Compared with wild-type controls, neurons in
hippocampal slices from tau knockout mice are more resistant
to disinhibition-induced bursting activity (Figure 3B), which
may be due, at least in part, to an increased frequency of spon-
taneous inhibitory postsynaptic currents in tau knockout mice
(Roberson et al., 2011). These findings suggest that tau has
a complex role in regulating neural network activity and that
tau reduction could prevent aberrant neuronal excitability,
network hypersynchrony or both.
The resistance of tau knockout mice to seizures may also
relate to alterations in brain oscillatory patterns. Tau knockout
mice have decreased peak frequency of theta waves in the
hippocampus and decreased coherence of gamma waves in
the frontal cortex (Cantero et al., 2010). The potential effects of
these alterations on Ab-induced dysrythmias and cognitive
abnormalities remain to be determined.
In conventional tau knockout mice, other MAPs might
compensate for tau loss, particularly MAP1A and MAP1B.
However, no changes inMAP1A,MAP1B, orMAP2 protein levels
were detected in 12-month-old adult tau knockout mice
(Dawson et al., 2001). To evaluate the safety of tau reduction
strategies for therapeutic purposes more conclusively, tau
needs to be reduced in adult mice after brain development and
maturation are complete, and such experiments are in progress.
In cultured cells, acute knockdown of tau did not affect the
stability or polymerization state of microtubules (King et al.,
2006; Qiang et al., 2006), and reducing tau levels in brains of
3-month-old wild-type mice for 12 weeks by methylene blue
administration caused no behavioral deficits in the rotarod test
or Morris water maze (O’Leary et al., 2010). Thus, it is unlikely
that loss of tau function is an important cause of neuronal
dysfunction or degeneration in AD and related conditions. In414 Neuron 70, May 12, 2011 ª2011 Elsevier Inc.fact, the findings summarized above suggest that partial
reduction of tau may be well tolerated and could effectively
protect the brain against Ab, epileptogenesis, and excitotoxicity.
Tau Functions Enabling Pathogenesis
In transgenic mice, wild-type levels of tau are required for Ab and
apoE4 to cause neuronal, synaptic, and behavioral deficits
(Andrews-Zwilling et al., 2010; Ittner et al., 2010; Roberson
Figure 3. Tau Reduction Suppresses Drug-Induced
Seizures in Mice and Neuronal Bursting Activity in
Disinhibited Hippocampal Slices
(A) Partial or complete reduction of tau in mice without hAPP
expression delayed the onset and reduced the severity of
seizures induced by pentylenetetrazole, a GABAA receptor
antagonist (Roberson et al., 2007).
(B) Tau knockout reduced aberrant neuronal discharges in
acute hippocampal slices after disinhibition with the GABAA
receptor antagonist bicuculline, as illustrated by measure-
ments of the coastline burst index (Roberson et al., 2011).
NTG, no hAPP expression; hAPPJ20, hAPP mice from line
J20.
Error bars represent standard error of the mean.
Neuron
Reviewet al., 2007, 2011). However, whether Ab and apoE4 contribute
to AD-related cognitive decline through the same or distinct
tau-dependent mechanism(s) remains to be determined. Acute
exposure of neuronal cultures to Ab led to hyperphosphorylation
(De Felice et al., 2008) and mislocalization of tau into dendritic
spines (Zempel et al., 2010), which, at least in some dendrites,
was associated with spine collapse and dendritic degeneration.
As tau phosphorylation releases tau from many of its binding
partners, it is tempting to speculate that tau is initially hyperphos-
phorylated in AD to reduce its function, in an effort to counteract
Ab-induced neuronal dysfunction. With time, though, this
compensatory mechanism fails because hyperphosphorylated
tau becomes detrimental at concentrations sufficient to form
toxic tau aggregates.
While tau is abnormally phosphorylated in apoE4 transgenic
mice (Brecht et al., 2004), we have so far found no evidence of
abnormal phosphorylation or aggregation of tau in hAPP-J20
mice, whose robust Ab-dependent neuronal and behavioral
deficits were prevented by reduction of wild-type murine tau
(Table 3 and Figure 4; Roberson et al., 2007, 2011). While we
continue to search for a direct pathogenic tau mediator and
a pathogenic mislocalization of tau in hAPP-J20 mice, the above
findings raise the possibility that physiological functions of
tau, rather than an abnormal tau gain of function (Figure 5),
permit Ab and other AD-related factors to elicit aberrant neuronal
excitation (Ittner et al., 2010; Roberson et al., 2007, 2011),
abnormalities in axonal transport (Vossel et al., 2010), and
impairment of inhibitory interneurons (Andrews-Zwilling et al.,
2010). Notably, even partial tau reduction improved longevity
and cognitive functions in hAPP-J20 mice (Figure 4; Roberson
et al., 2007). Tau knockout also improved longevity and cognitive
functions in APP23 mice and in both lines markedly increased
resistance to seizures in mice with or without hAPP (Ittner
et al., 2010; Roberson et al., 2007, 2011). For unclear reasons,
tau reduction was not beneficial in the Tg2576 hAPP mouse
model (Dawson et al., 2010).
The tyrosine kinase Fyn appears to be important in the devel-
opment of Ab- and tau-dependent neuronal deficits. Neuronal
overexpression of Fyn sensitizes hAPP mice to Ab-induced
neuronal, synaptic, and cognitive deficits (Chin et al., 2004,
2005) that are prevented by knocking out tau in hAPP-J9/FYN
doubly transgenic lines (Roberson et al., 2011). Tau knockout
prevented behavioral deficits in the Morris water maze and
elevated plus maze of hAPP/FYN mice and premature mortalityin two separate lines of hAPP/FYN mice (Roberson et al., 2011).
In addition, tau knockout prevented spontaneous epileptic
activity in hAPP/FYN mice and hAPP-J20 mice (Table 3;
Roberson et al., 2011). This striking antiepileptic effect could
result from the reduction of tau in axons, dendrites, or both.
Although tau knockout did not affect axonal transport at baseline
(Vossel et al., 2010; Yuan et al., 2008), it precluded Ab-induced
deficits in the axonal transport of cargoes that could affect
neuronal excitability (Figure 4D; Vossel et al., 2010). Tau is also
required for Fyn to gain access to and phosphorylate the
NR2B subunit of dendritic NMDA receptors (Ittner et al., 2010).
Consistent with our hypothesis that tau reduction protects
against Ab by preventing neuronal overexcitation (Roberson
et al., 2007), targeted perturbation of the NR/PSD-95 interaction,
which prevents excitotoxicity, also prevented premature
mortality and memory deficits in APP23 mice (Ittner et al.,
2010). These findings suggest that modulating tau, its interaction
with Fyn, or key proteins involved in or affected by this interaction
may be of therapeutic benefit in AD.
The interaction between Fyn and tau may also contribute to
FTLD. Several forms of FTLDmutant tau and pseudohyperphos-
phorylated tau bind Fyn more tightly than wild-type tau (Bhaskar
et al., 2005), which may increase neuronal Fyn activity. Further-
more, Fyn binds more tightly to 3R0N tau than 4R0N tau
(Bhaskar et al., 2005), implying that FTLD mutations that alter
tau splicing could also alter the activity or localization of Fyn. In
mice overexpressing P301L 4R0N tau under the mouse prion
promoter (JNPL3 model), phosphorylation of tau at Y18 by Fyn
increases simultaneously with tau hyperphosphorylation on
serine/threonine sites before the onset of behavioral deficits
(Bhaskar et al., 2010).
The physiological actin-bundling function of tau may also
contribute to pathology. Filamentous actin inclusions, closely
resembling Hirano bodies in AD, were found in Drosophila
models overexpressing wild-type or R406W 4R0N tau and in
mice overexpressing P301L 4R0N tau under the TRE promoter
with the tet-off element under the CaMKII promoter (rTg4510
model) (Fulga et al., 2007). Knocking out or destabilizing actin
filaments in Drosophilamodels prevented tau-induced degener-
ation (Fulga et al., 2007), implicating alterations in actin dynamics
as a mediator of tau toxicity.
Abnormal Gain of Function
The largest amount of work in this field has focused on tau
phosphorylation and aggregation. Tau is highly phosphorylatedNeuron 70, May 12, 2011 ª2011 Elsevier Inc. 415
Figure 5. Potential Mechanisms of Tau-Dependent Ab Toxicity
Experiments in which neuronswere acutely exposed to Ab suggest that Ab can
trigger tau-mediated neurotoxicity by enhancing tau phosphorylation, which in
turn directs pathogenic tau species into dendritic spines where they exert
adverse effects (left). In hAPP mice though, in which neurons are chronically
exposed to elevated Ab levels, it has so far been difficult to find clear evidence
for a similar process. Nonetheless, Ab-induced neuronal dysfunction in these
models strictly depends on the presence of tau, raising the possibility that
physiological functions of tau permit Ab to cause neuronal dysfunction (right).
Such functionsmay involve the intraneuronal trafficking of factors that regulate
synaptic activity at the pre- or postsynaptic level.
Figure 4. Tau Reduction Does Not Change
Amyloid Pathology but Prevents Ab-Dependent
Cognitive and Functional Neuronal Deficits
Tau reduction did not affect (A) Ab deposition or (B) the
number of plaques with dystrophic neurites (DN) in hAPP-
J20 mice. However, even partial tau reduction prevented
(C) memory deficits in the Morris water maze (72 hr probe
trial) in hAPP-J20 mice (**p < 0.01, ***p < 0.001 versus
other quadrant; ANOVA, Tukey) (Roberson et al., 2007)
and (D) Ab oligomer-induced axonal transport deficits in
primary hippocampal neurons, although it had no effect
on axonal transport at baseline (***p < 0.001, indicates
comparison to baseline within the genotype; paired t tests
with Bonferroni correction. #p < 0.05, ##p < 0.01 versus
Ab-treated Tau+/+; Kruskal-Wallis analysis of variance,
Dunn) (Vossel et al., 2010). Error bars represent standard
error of the mean.
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lated on many sites in adult brain, albeit with lower frequency
(Matsuo et al., 1994; Yu et al., 2009). Tau is transiently hyper-
phosphorylated during hibernation without long-term harm to
neural networks (Arendt et al., 2003). Tau phosphorylation is
also markedly increased in response to various stressors. In
humans, tau becomes hyperphosphorylated and aggregated
after head trauma, following earlier increases in APP expression,
axonal swelling, and microtubule disruption (Gentleman et al.,
1993; Omalu et al., 2011). Tau also becomes hyperphosphory-
lated in mouse brain in response to hypothermia and experi-
mental insulin-dependent diabetes (Planel et al., 2007). In cell
culture and brain slice models of neuronal injury, tau is hyper-
phosphorylated during recovery from heat shock (Miao et al.,
2010), in response to Ab oligomer treatment (De Felice et al.,
2008; Zempel et al., 2010), hypoxia, and glucose deprivation
(Burkhart et al., 1998). In cell culture, ATP, glutamate, hydrogen
peroxide, serum deprivation and Ab oligomer treatment all cause
taumislocalization into dendrites (Zempel et al., 2010), a process
that is likely triggered by hyperphosphorylation-induced dissoci-
ation of tau from microtubules and cell membranes. Thus,
increased phosphorylation and redistribution of tau may be
common responses to neuronal stress.
Findings in Drosophila models suggest that tau phosphoryla-
tion may cause neurotoxicity in a combinatorial fashion rather
than through the modification of individual phosphorylation sites
and involves the folding of tau into an abnormal conformation
resembling tau conformations found in AD (Steinhilb et al.,
2007). Hyperphosphorylated tau has a tighter, more folded
conformation and an increased propensity to aggregate (Jega-
nathan et al., 2008), as does tau with mutations found in FTLD
(Lee et al., 2001). In C. elegans, overexpression of wild-type or
mutant 4R1N tau causes axonal degeneration and an uncoordi-
nated phenotype indicative of neuronal dysfunction (Kraemer
et al., 2003). The extent of phosphorylation was similar across
mutant and wild-type tau lines, but more insoluble tau was found
in the former (Kraemer et al., 2003). Worms overexpressing
mutant tau that formed aggregates had a more severe pheno-
type (Kraemer et al., 2003).416 Neuron 70, May 12, 2011 ª2011 Elsevier Inc.Although filamentous tau inclusions are a pathologic hallmark
of tauopathies, experimental evidence suggests that filamentous
taumay not be responsible for neuronal dysfunction. In a regulat-
able P301L 4R0N tau transgenic mouse (rTg4510 model), inhib-
iting tau production after filamentous tau inclusions formed
reversed behavioral deficits in the Morris water maze, even
though inclusion formation progressed (Santacruz et al., 2005).
Acute tau reduction by methylene blue treatment in this model
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soluble tau in the brain but did not alter the number or length
of tau fibrils or the amount of Sarkosyl-insoluble tau compared
to untreated transgenic mice (O’Leary et al., 2010). In other
mouse lines, tet-off transgenes were regulated by the CaMKII
promoter to express either the 4R microtubule repeat domain
of human tau with a deletion of lysine 280 (termed TauRD), which
is highly prone to aggregation, or TauRD with an additional
two mutations (I277P/I308P) that prevent its aggregation
(Mocanu et al., 2008). The proaggregation transgenic mouse,
which formed hyperphosphorylated tau inclusions containing
TauRD and endogenous mouse tau, developed synaptic loss
(Mocanu et al., 2008), memory deficits and electrophysiological
impairments (Sydow et al., 2011). In contrast, the antiaggrega-
tion transgenic mouse showed none of these abnormalities.
Turning off the transgene in the proaggregation mouse reversed
behavioral and electrophysiological alterations without elimi-
nating insoluble tau aggregates, which were composed entirely
of endogenous mouse tau after the transgene had been turned
off for 4 months (Sydow et al., 2011). These data highlight that
tau aggregation causes toxicity, possibly through the formation
of tau oligomers.
This conclusion is supported by studies using in vivo two-pho-
ton microscopy demonstrating that very few neurons containing
tau inclusions in regulatable rTg4510 transgenic mice have
caspase activation or membrane disruption (de Calignon
et al., 2009, 2010). Decreasing the levels of soluble tau reduced
caspase activation in inclusion-positive neurons without
affecting the number or size of tau inclusions (de Calignon
et al., 2010), implicating soluble tau, not tau inclusions, in the
activation of proapoptotic pathways. Neurons with or without
tau inclusions in this regulatable P301L tau model showed
similar electrophysiological deficits, relative to wild-type neurons
(Rocher et al., 2010). Studies in young transgenic flies overex-
pressing wild-type or mutant 4R0N tau constructs also indicated
that toxicity was conferred by soluble tau species, possibly
dimers (Feuillette et al., 2010).
Collectively, these studies suggest that tau inclusions are not
very toxic and that neuronal toxicity is caused by a smaller,
soluble aggregate or a specific conformation of tau. Tau oligo-
mers have been identified in in vitro and in vivo models as well
as in AD brains (Berger et al., 2007; Maeda et al., 2007; Sahara
et al., 2008). In regulatable P301L 4R0N transgenic mice
(rTg4510 model), the extent of memory deficits correlated with
the level of putative tau oligomers (Berger et al., 2007).
Tau can also be cleaved in various places by caspase-3,
calpain, and cathepsin L, and several of the resulting fragments
are thought to increase tau aggregation. In primary neurons
exposed to Ab, calpain generates a 17-kDa tau fragment (Park
and Ferreira, 2005). However, the toxicity and in vivo relevance
of this fragment are debated; its presence is variable in both
control and AD brains (Garg et al., 2011) and it appears to be
absent from brains of hAPP-J20 mice (Roberson et al., 2007).
Ab treatment of cortical neurons causes caspase cleavage of
tau at Asp421, and cleavage at this site facilitates the formation
of tau aggregates in cell-free conditions (Gamblin et al., 2003).
Caspase activation precedes formation of filamentous tau inclu-
sions in P301L 4R0N tau transgenic mice (rTg4510 model),raising the possibility that caspase cleavage is important for
aggregation of FTLD mutant tau in vivo (de Calignon et al.,
2010). In an inducible cell culture model overexpressing the
microtubule repeat domain of tau missing K280, cytosolic
cleavage by unknown proteases generated putative tau oligo-
mers associated with lysosomal membranes and inhibited chap-
erone-mediated autophagy; smaller fragments produced by
cathepsin L seeded tau aggregation (Wang et al., 2009).
Tau may also exert toxic effects from the extracellular milieu
(Frost et al., 2009; Go´mez-Ramos et al., 2006). The death of de-
generating neurons or extrusion of tau from living cells contain-
ing tau aggregates may result in the release of pathogenic tau
species into the extracellular space, where they may adversely
affect neighboring cells. For example, a peptide in the C terminus
of tau (amino acids 391–407) increased intracellular calcium
concentrations by activating the muscarinic receptors M1 and
M3 (Go´mez-Ramos et al., 2008). Tau aggregates released from
cells were taken up by and triggered tau aggregation within
co-cultured cells that had no pre-existing tau aggregates (Frost
et al., 2009).
Injection of insoluble P301S human 4R0N tau from transgenic
mouse brainstem extracts into the hippocampus of transgenic
mice expressing wild-type 4R2N human tau under the mouse
Thy1.2 promoter caused intraneuronal formation of wild-type
4R2N human tau inclusions in the hippocampus that spread
along synaptic connections to distant brain regions (Clavaguera
et al., 2009). However, we are unaware of any evidence that this
transfer of tau aggregation causes neuronal dysfunction or
neurodegeneration. Injecting soluble P301S tau into the trans-
genic mice or insoluble P301S tau into nontransgenic mice failed
to cause extensive pathology.
Thus, injection of insoluble tau into the brain parenchyma
triggers propagation of tau pathology along neuronal pathways,
but only in the presence of the correct tau template. It is unknown
whether the potential progression of AD from one brain region to
another (Braak and Braak, 1997) depends on similar processes,
the presynaptic release of Ab (Harris et al., 2010), or other mech-
anisms.
Do FTLD Mutations Simulate Tau Pathology in AD?
Interestingly, mutations in the tau gene cause FTLD disorders
such as progressive supranuclear palsy, corticobasal degenera-
tion, and frontotemporal dementia, but never AD. While the
clinical spectrum associated with the many rare tau mutations
varies, most FTLD disorders differ from AD both in the types of
tau inclusions and in the brain regions affected (Mann et al.,
2001), indicating a possible divergence in the roles of tau in these
conditions. The trigger for increased phosphorylation and aggre-
gation of tau is also likely different in AD and FTLD.
Two recent studies set out to compare the consequences of
overexpressing wild-type human 4R2N tau versus P301Lmutant
human 4R2N tau in transgenic mice. Each group generated two
mouse lines with approximately matched tau expression levels
and patterns directed by the Thy1 promoter (Terwel et al.,
2005) or the CaMKII promoter (Kimura et al., 2010). In both
studies, P301L tau mice differed from wild-type tau mice in tau
phosphorylation patterns and in that P301L tau aggregated
more readily than wild-type tau, consistent with previousNeuron 70, May 12, 2011 ª2011 Elsevier Inc. 417
Table 4. Tau-Targeted Therapies in Clinical Trialsa
Target Drug Diagnosis
Goal Sample
Size
Treatment
Duration Stage Status/Outcome
Tau phosphorylation
by GSK3b
Lithium ± Divalproex AD 35 6 weeks Phase II Completed, not yet published
Lithium MCI 80 2 years Phase II Ongoing
Lithium PSP, CBD 17 28 weeks Phase I/II Completed, not yet published
Lithium Mild AD 71 10 weeks RCT Completed. No effect on lymphocyte
GSK3 activity or CSF p-tau
(Hampel et al., 2009)
Microtubule stabilization/
tau phosphorylation
NAP, AL-108 MCI 120 12 weeks Phase II Completed, not yet published
PSP 300 52 weeks Phase II/III Recruiting
FTLD-tau,
PSP, CBD
12 12 weeks
(pilot)
Phase II Ongoing
Tau aggregation Methylene blueb AD 321 50 weeks Phase II Completed, not yet published
CBD, corticobasal degeneration; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; PSP, progressive supranuclear palsy; p-tau, phosphory-
lated tau; RCT, randomized placebo-controlled trial.
a Based on www.clinicaltrials.gov and PubMed search.
bMay also reduce soluble tau levels.
Neuron
Reviewfindings (von Bergen et al., 2001). Remarkably, in both studies,
behavior was impaired earlier in wild-type tau transgenic
mice than in P301L tau transgenic mice, even though tau was
similarly expressed under the same promoter and only P301L
mutant tau transgenic mice had tau aggregates. Thy1-wild-
type tau mice had early motor impairments and axonopathy,
whereas Thy1-P301L tau mice had late motor impairments,
insoluble tau inclusions, and no axonopathy (Terwel et al.,
2005). CaMKII-wild-type tau mice had earlier memory deficits
in the Morris water maze and synaptic loss than CaMKII-P301L
tau mice, but tau inclusions and neuronal loss were observed
only in CaMKII-P301L tau mice (Kimura et al., 2010). These find-
ings suggest that P301L tau causes neuronal loss through its
propensity to aggregate and, possibly, to form toxic oligomeric
tau species, whereas wild-type human tau may cause early
neuronal and cognitive dysfunction without neuronal cell death,
possibly by enhancing normal functions of tau or altering the
regulation of endogenous tau.
Another recent study compared transgenic mice expressing
P301L human 4R0N tau (rTg4510 model) or wild-type human
4R0N tau directed by the TRE promoter and tTA (tet-off) directed
by the CaMKII promoter. Both lines showed deficits in the Morris
water maze; however, the deficits worsened with aging in the
P301L tau line but not in the wild-type tau line (Hoover et al.,
2010). As in the lines described above, neurodegeneration was
identified only in the P301L tau line but not in the wild-type tau
line. In primary cultures, neurons expressing P301L tau showed
tau in dendritic spines more frequently and had greater reduc-
tions of miniature excitatory postsynaptic potentials (mEPSCs)
and of dendritic GluR1, GluR2/3, and NR1 levels than neurons
expressing wild-type tau (Hoover et al., 2010). Tau phosphoryla-
tion was required for tau to enter into dendritic spines and to
impair mEPSCs in transfected primary rat neurons (Hoover
et al., 2010).
In slice cultures, wild-type human 3R0N tau and R406W
human 4R2N tau each enhanced Ab-induced neuronal cell death
in the hippocampal CA3 region, whereas P301L human 4R2N tau418 Neuron 70, May 12, 2011 ª2011 Elsevier Inc.did not (Tackenberg and Brandt, 2009). A 3R0N tau mutant that
prevents phosphorylation and a 3R0N tau mutant that mimics
hyperphosphorylation showed no synergistic neurotoxic effect
with Ab, implying that dynamic tau phosphorylation may be
required for the enhancement of Ab toxicity by tau (Tackenberg
and Brandt, 2009). These results are consistent with findings
indicating that tau requires phosphorylation to enter the dendritic
spine in order to affect synaptic function (Hoover et al., 2010)
and that Ab oligomers acutely increase phosphorylation and
pathogenic enrichment of wild-type tau in dendritic spines
(Zempel et al., 2010).
It may be that P301L tau is already phosphorylated and
present in dendritic spines, and therefore no further toxicity is
seen in the presence of Ab oligomers. Interestingly, the adverse
effects of wild-type tau were dependent on the activity of both
NMDAR and GSK3b, whereas the effects of R406W tau were
dependent only on NMDAR activity, suggesting partly distinct
mechanisms of toxicity (Tackenberg and Brandt, 2009).
These results imply that AD-relevant pathogenic mechanisms
and therapeutic opportunities might be missed in FTLD mutant
transgenic mice due to overriding effects of the FTLDmutations.
Treatments Targeting Tau
Treatments targeting various aspects of tau biology are under
intense investigation. Inhibitors of tau phosphorylation and
aggregation and microtubule stabilizers are already in clinical
trials for people with mild cognitive impairment, AD, or FTLD
(Table 4), while tau reduction strategies are still in preclinical
stages of development. As we learn more about how tau expres-
sion is regulated and about tau’s involvement in cell signaling
and cytoskeletal organization, additional approaches are likely
to emerge.
Tau Phosphorylation Inhibitors
The function and aggregation of tau appear to be regulated by
phosphorylation, as reviewed above. Of the numerous tau
kinases implicated in AD pathogenesis, the most widely studied
are GSK-3b, CDK5, MARK, andMAPK (Augustinack et al., 2002;
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ReviewMi and Johnson, 2006). Lithium, which inhibits GSK-3b and is
used to treat bipolar disorder, improved behavior and reduced
tau pathology in transgenic mice overexpressing P301L human
4R0N tau (JNPL3 model) (Noble et al., 2005). However, because
lithium has multiple targets, the rescue observed may not
have been solely due to a reduction in GSK3b activity. Lithium
also has a narrow safety margin (Grandjean and Aubry, 2009).
In addition, reduction of GSK-3b impairs NMDAR-mediated
long-term depression (Peineau et al., 2007) and memory consol-
idation (Kimura et al., 2008), raising concerns about potential
side effects of GSK-3b inhibitors. In a similar vein, CDK5 inhibi-
tors prevent Ab-induced hyperphosphorylation of tau and cell
death in culture (Alvarez et al., 1999; Zheng et al., 2005), but
CDK5 is essential for multiple cell signaling pathways and adult
neurogenesis, limiting its appeal as a tau-targeting approach in
AD. However, CDK5 and p25, a truncated form of the CDK5
subunit p35, also promote neurodegeneration through mecha-
nisms that are independent of tau phosphorylation, involving
inhibition of histone deacetylase 1 (HDAC1) and aberrant expres-
sion of cell cycle genes (Kim et al., 2008), raising possibilities for
additional therapeutic intervention.
Tau Aggregation Inhibitors
In vitro, tau aggregation is induced by polyanionic compounds
such as RNA (Kampers et al., 1996), heparin (Crowe et al.,
2007; Goedert et al., 1996; Pe´rez et al., 1996), and lipid micelles
(Chirita et al., 2003). Many of the drugs that block the aggrega-
tion of tau also block the pathological aggregation of other
proteins under cell-free conditions, including Ab and a-synuclein
(Masuda et al., 2006), suggesting that they might be of benefit in
diverse proteinopathies. Some tau aggregation inhibitors are
effective in Neuro2A cell lines overexpressing a 4R tau micro-
tubule repeat domain fragment with a K280 deletion, which
promotes its aggregation (Pickhardt et al., 2005). In human AD
patients, the phenothiazine methylene blue showed some
promise for slowing disease progression in a phase II clinical trial
conducted for 1 year (Gura, 2008). Methylene blue was originally
thought to inhibit tau-tau interactions (Wischik et al., 1996), but it
may also reduce soluble tau through other mechanisms (O’Leary
et al., 2010) as it is known to have many targets (Schirmer et al.,
2011). Phase III trials with a newer formulation of methylene blue
(LMTX) are planned (Wischik, 2002).
The immunosuppressant FK506 reduces microgliosis and
tau aggregation in transgenic mice overexpressing P301S
human 4R1N tau under the mouse prion promoter (PS19 model)
(Yoshiyama et al., 2007). Since FK506 affects diverse signaling
pathways in many cell types, it may act directly on neurons or
influence the neuronal environment by modulating glial activa-
tion. Inhibition of tau aggregationmay also bemediated by direct
binding of tau to the FK506 binding protein 52 (Chambraud et al.,
2010).
As discussed above, it is far from certain that filamentous tau
is actually toxic. Indeed, it is not known which tau assembly
or conformation is responsible for tau-dependent neuronal
dysfunction and degeneration. Not surprisingly, it is equally
uncertain whether the abundance of this entity is lowered by
any of the available tau aggregation blockers. In fact, some tau
aggregation inhibitors enhance the formation of potentially toxic
tau oligomers (Taniguchi et al., 2005). This scenario is reminis-cent of the current state of anti-Ab treatment, where it is also
unclear whether any of the anti-Ab strategies that have under-
gone or are currently in clinical trials significantly reduce the
abundance of Ab oligomers in human brain tissues, which are
suspected to be the main mediators of Ab-induced neuronal
dysfunction (Ashe and Zahs, 2010; Cheng et al., 2007; Sakono
and Zako, 2010; Shankar et al., 2008).
Reduction of Overall Tau Levels
In mice, partial reduction of tau during early development is well
tolerated, increases resistance to chemically induced seizures,
and markedly diminishes Ab- and ApoE4-induced neuronal
and cognitive impairments in vivo (Andrews-Zwilling et al.,
2010; Ittner et al., 2010; Roberson et al., 2007, 2011). Assuming
ongoing experiments confirm that reduction of overall tau levels
is efficacious and safe also when initiated in adult and old
animals with AD-related pathologies, tau could be targeted
directly with RNAi approaches in patients with AD. Alternatively,
tau levels could be reduced indirectly by targetingmolecules that
regulate the expression or clearance of tau.
Tau is thought to be degraded via the ubiquitin-proteasome
and lysosomal pathways. The ubiquitin ligase for tau was identi-
fied as the C terminus of HSP70-interacting protein (CHIP)
(Hatakeyama et al., 2004; Petrucelli et al., 2004; Shimura et al.,
2004). Reduction of CHIP levels increased the accumulation of
tau aggregates in P301L human 4R0N tau mice (JNPL3 model),
and CHIP levels are reduced in AD brains (Sahara et al., 2005).
Furthermore, as its name suggests, CHIP works in combination
with heat shock proteins to regulate tau degradation (Dickey
et al., 2007); levels of heat shock protein 90 (Hsp90) correlate
inversely with the levels of soluble tau and tau oligomers (Sahara
et al., 2007b).
In AD brains, tau is hyperacetylated, which should increase its
half-life (Min et al., 2010), alter its microtubule binding and
enhance aggregation (Cohen et al., 2011). Because both acety-
lation and ubiquitination modify lysine residues, acetylation of
tau by the acetyl transferase p300 inhibits ubiquitination and
stabilizes tau (Min et al., 2010). In addition, acetylation of the 6
amino acid motif VQIINK (PHF6*) inhibits the binding of tau to
microtubules and enhances tau aggregation (Cohen et al.,
2011). This motif is critical for the formation of tau oligomers
and filaments (Sahara et al., 2007a; von Bergen et al., 2001).
Thus, the combination of a tau acetylation inhibitor and a ubiqui-
tination-proteasome enhancer might synergize to lower the level
of pathogenic tau species.
Larger aggregates of tau are not likely to be accessible to the
proteasome but can be degraded by the lysosomal pathway, in
which autophagosomes engulf the aggregates and fuse with
lysosomes. In cells overexpressing the microtubule repeat
domain of tauwith a deletion of K280, aggregated tau is removed
by the lysosomal pathway (Wang et al., 2009). In slice culture,
inhibition of the lysosomal pathway produces NFT-like tau depo-
sition (Bi et al., 1999). The lysosomal pathway of tau degradation
is also involved in Niemann-Pick type C (NPC) disease, an auto-
somal recessive disorder associated with neurological symp-
toms and NFT formation in the brain (Auer et al., 1995). NPC
disease is caused by a loss of function of NPC1, a lysosomal traf-
ficking protein (Pacheco and Lieberman, 2008), suggesting that
tau is degraded in lysosomes and that lysosomal dysfunctionNeuron 70, May 12, 2011 ª2011 Elsevier Inc. 419
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phorylated tau is increased in the brains of NPC1-deficient
mice and of NPC patients (Bu et al., 2002). However, cross-
breeding of NPC1-deficient mice with tau knockout mice wors-
ened the phenotype (Pacheco et al., 2009), suggesting that the
role of tau in this disease is complex. The autophagic-lysosomal
pathway has also been interrogated in a Park2-deficient tauop-
athy model with parkinsonism overexpressing mutant human
4R2N tau under the mouse Thy1 promoter (PK//TauVLW)
(Rodrı´guez-Navarro et al., 2010). Treatment of 3-month-old
PK//TauVLW mice with trehalose, an mTOR-independent
autophagy activator, for 2.5 months prevented dopaminergic
neuron loss in the ventral midbrain, reduced phosphorylated
tau and total tau in the striatum and limbic system, prevented
brain astrogliosis, and improved motor and cognitive behavior.
Biochemical and electron microscopy data suggested that the
protective effects of trehalose were mediated, at least in part,
by autophagy activation (Rodrı´guez-Navarro et al., 2010).
Tau degradation can also be enhanced by specific activation
of the immune system. Active immunization targeting phosphor-
ylated tau reduced filamentous tau inclusions and neuronal
dysfunction in transgenic mice overexpressing K257T/P301S
human 4R0N tau under the rat tau promoter or P301L human
4R0N tau (JNPL3 model) (Asuni et al., 2007; Boimel et al.,
2010). The mechanism by which intracellular proteins, including
tau and a-synuclein, are cleared by immunization is not known
but may involve lysosomal degradation (Masliah et al., 2005;
Sigurdsson, 2008, 2009). Once antibodies enter into brain, they
could be taken up by receptor-mediated endocytosis and acti-
vate autophagy (Sigurdsson, 2009) or interact with tau in the
extracellular matrix. Extracellular tau in cerebrospinal fluid
(CSF) is used in combination with other biomarkers to diagnose
AD (Trojanowski et al., 2010); phosphorylated tau and total tau
levels in the CSF can also predict disease severity (Wallin
et al., 2010). Extracellular tau could come from the death of
neurons or be released from live cells (Kim et al., 2010). If there
is an equilibrium between intracellular and extracellular tau,
clearance of tau/antibody complexes from the extracellular
space may ultimately lower intracellular tau levels (Brody and
Holtzman, 2008; Sigurdsson, 2009).
Microtubule Stabilizers
Microtubule disruption has been observed in several models of
AD and FTLD, including transgenic mice overexpressing wild-
type human 0N3R tau under the mouse prion promoter (T44
model) (Zhang et al., 2005) or P301S human 4R1N tau (PS19
model) (Yoshiyama et al., 2007) and wild-type neuronal cultures
exposed to Ab oligomers (King et al., 2006; Zempel et al., 2010).
Some FTDP-17 tau mutations (Hong et al., 1998) and tau hyper-
phosphorylation (Alonso et al., 1994; Merrick et al., 1997) reduce
the binding of tau to microtubules. Although tau overexpression
seems to be associated with destabilization of microtubules, it is
unclear whether this phenomenon is always pathogenic and
whether it results from a loss- or gain-of-function of tau. Indeed,
tau is necessary for Ab-inducedmicrotubule disassembly in vitro
(King et al., 2006), suggesting that tau is actually required
for microtubule destabilization. A loss-of-function mechanism
seems also unlikely because tau knockout mice have a rather
benign phenotype, and tau reduction protects neurons from420 Neuron 70, May 12, 2011 ª2011 Elsevier Inc.Ab-induced impairments in vitro (King et al., 2006; Rapoport
et al., 2002; Vossel et al., 2010), ex vivo (Shipton et al., 2011),
and in vivo (Ittner et al., 2010; Roberson et al., 2007, 2011).
Despite these caveats regarding underlying mechanism,
microtubule stabilizers have shown promise in preclinical and
clinical trials for AD. For example, paclitaxel prevented
Ab-induced toxicity in vitro (Zempel et al., 2010) as well as axonal
transport deficits and motor impairments in transgenic mice
overexpressing wild-type human 0N3R tau (T44 model) (Zhang
et al., 2005). Epothilone D, which has better blood-brain barrier
permeability, improved microtubule density and cognition in
P301S human 4R1N tau mice (PS19 model) (Brunden et al.,
2010). The peptide NAP stabilizes microtubules (Divinski et al.,
2006) and reduces tau hyperphosphorylation (Vulih-Shultzman
et al., 2007), suggesting that microtubule-stabilizing compounds
can have more than one mechanism of action. NAP can be
administered intranasally and showed some promise in a phase
II clinical trial (Gozes et al., 2009).
Conclusions
While tau has long been implicated in neurodegenerative condi-
tions, its functions in the adult brain and the precise mecha-
nisms by which it contributes to neuronal dysfunction and
degeneration in these disorders remain to be elucidated. A flurry
of recent publications has challenged major dogmas in this field,
including the notion that filamentous tau aggregates are the
most pernicious forms of tau, that loss of tau function plays
a major role in the pathogenesis of tauopathies, that tau enters
dendritic spines only under pathological circumstances, and
that the adverse activities of tau aggregates are restricted to
intracellular compartments. Provocative discoveries suggest
that tau regulates neuronal excitability and that it is required
for Ab and other excitotoxins to cause neuronal deficits, aber-
rant network activity and cognitive decline. Indeed, tau has
‘‘graduated’’ from a putative microtubule stabilizer to a multi-
functional protein with many interacting signaling networks
and to a master regulator of the intracellular trafficking of organ-
elles and molecules involved in synaptic functions at the pre-
and postsynaptic level. The hunt has also been intensified for
the most pathogenic forms of tau, some of which have been
traced into dendritic spines, and more has been learned about
the complex posttranslational modification of tau, particularly
acetylation, which appears to regulate the ubiquitination, turn-
over, and aggregation of tau. These and other findings are
providing critical guidance in the development of better treat-
ments for tauopathies aimed at tau itself, tau regulators or
factors mediating its putative functions. Identifying the functions
and precise roles of tau in neurodegenerative disorders will likely
require the analysis of conditional knockout models and the
clinical evaluation of pertinent drugs with well defined modes
of action.
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